(Q38679294)

5 September 2017

Epithelial Mesenchymal Transition in Aggressive Lung Cancers (English)

1 reference

5 September 2017

Vivek Mittal

1

1 reference

PubMed ID

26703798

5 September 2017

language of work or name

English

0 references

publication date

1 January 2016

1 reference

Advances in Experimental Medicine and Biology

5 September 2017

1 reference

5 September 2017

890

1 reference

5 September 2017

37-56

1 reference

Epithelial-mesenchymal transitions: insights from development

5 September 2017

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Epithelial--mesenchymal and mesenchymal--epithelial transitions in carcinoma progression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Epithelial-mesenchymal transitions in development and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Molecular mechanisms of epithelial-mesenchymal transition

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Growth factors in induction of epithelial-mesenchymal transition and metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Regulatory networks defining EMT during cancer initiation and progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

The ins and outs of the epithelial to mesenchymal transition in health and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

The epigenetics of epithelial-mesenchymal plasticity in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

A systems view of epithelial-mesenchymal transition signaling states

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Epithelial-mesenchymal transition, cancer stem cells and treatment resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

The epithelial-mesenchymal transition generates cells with properties of stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Generation of breast cancer stem cells through epithelial-mesenchymal transition

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Tumor microenvironment regulates epithelial-mesenchymal transitions in metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Microenvironmental regulation of epithelial-mesenchymal transitions in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Versican mediates mesenchymal-epithelial transition

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

EMT in carcinoma progression and dissemination: facts, unanswered questions, and clinical considerations

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

To differentiate or not--routes towards metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Cancer theory faces doubts

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

The fallacy of epithelial mesenchymal transition in neoplasia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

The basics of epithelial-mesenchymal transition

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Mesenchymal to epithelial transition in development and disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Expression pattern of adhesion molecules (E-cadherin, alpha-, beta-, gamma-catenin and claudin-7), their influence on survival in primary breast carcinoma, and their corresponding axillary lymph node metastasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Phenotypic plasticity and epithelial-mesenchymal transitions in cancer and normal stem cells?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

EMT and dissemination precede pancreatic tumor formation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Direct Evidence for Epithelial-Mesenchymal Transitions in Breast Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

31 March 2020

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Prognostic role of Twist, Slug, and Foxc2 expression in stage I non-small-cell lung cancer after curative resection

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Overexpression of FOXM1 is associated with EMT and is a predictor of poor prognosis in non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

[Epithelial-mesenchymal transition in non-small cell lung cancer]

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Periostin expression and epithelial-mesenchymal transition in cancer: a review and an update

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Epithelial-mesenchymal transition-associated secretory phenotype predicts survival in lung cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Downregulation of BRAF activated non-coding RNA is associated with poor prognosis for non-small cell lung cancer and promotes metastasis by affecting epithelial-mesenchymal transition

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

JAK/STAT3 signaling is required for TGF-β-induced epithelial-mesenchymal transition in lung cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Peroxisome proliferator-activated receptor-gamma activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Epithelial to mesenchymal transition by TGFβ-1 induction increases stemness characteristics in primary non small cell lung cancer cell line

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Prognostic value of cancer stem cells, epithelial-mesenchymal transition and circulating tumor cells in lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

TGF-β1 exposure induces epithelial to mesenchymal transition both in CSCs and non-CSCs of the A549 cell line, leading to an increase of migration ability in the CD133+ A549 cell fraction.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Neuropilin-2 Is upregulated in lung cancer cells during TGF-β1-induced epithelial-mesenchymal transition

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Snail regulates Nanog status during the epithelial-mesenchymal transition via the Smad1/Akt/GSK3β signaling pathway in non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Alterations of the Notch pathway in lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Notch signaling in lung development and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Notch signaling mediates hypoxia-induced tumor cell migration and invasion

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Rhamnetin and cirsiliol induce radiosensitization and inhibition of epithelial-mesenchymal transition (EMT) by miR-34a-mediated suppression of Notch-1 expression in non-small cell lung cancer cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Delta-tocotrienol suppresses Notch-1 pathway by upregulating miR-34a in nonsmall cell lung cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Opposing role of Notch1 and Notch2 in a KrasG12D-driven murine non-small cell lung cancer model

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Upregulation of notch2 and six1 is associated with progression of early-stage lung adenocarcinoma and a more aggressive phenotype at advanced stages

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

MiR-132 suppresses the migration and invasion of lung cancer cells via targeting the EMT regulator ZEB2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

miR-200 enhances mouse breast cancer cell colonization to form distant metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Osteopontin Expression and Prognostic Significance in Non-Small Cell Lung Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Osteopontin increases lung cancer cells migration via activation of the alphavbeta3 integrin/FAK/Akt and NF-kappaB-dependent pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

PTTG induces EMT through integrin αVβ3-focal adhesion kinase signaling in lung cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Zyxin is a transforming growth factor-β (TGF-β)/Smad3 target gene that regulates lung cancer cell motility via integrin α5β1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

The inflammatory tumor microenvironment, epithelial mesenchymal transition and lung carcinogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Smoking induces epithelial-to-mesenchymal transition in non-small cell lung cancer through HDAC-mediated downregulation of E-cadherin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Cigarette smoke-induced alveolar epithelial-mesenchymal transition is mediated by Rac1 activation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Epilysin (MMP-28) induces TGF-beta mediated epithelial to mesenchymal transition in lung carcinoma cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Matrilysin (matrix metalloproteinase-7) mediates E-cadherin ectodomain shedding in injured lung epithelium

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Matrix metalloproteinase-induced fibrosis and malignancy in breast and lung

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Matrix metalloproteinase induction of Rac1b, a key effector of lung cancer progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Molecular correlates of gefitinib responsiveness in human bladder cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Expression of snail in pancreatic cancer promotes metastasis and chemoresistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Ran GTPase induces EMT and enhances invasion in non-small cell lung cancer cells through activation of PI3K-AKT pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

High NOTCH activity induces radiation resistance in non small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Hedgehog/Gli promotes epithelial-mesenchymal transition in lung squamous cell carcinomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Retracted: Up-Regulation of Sonic Hedgehog Contributes to TGF-β1-Induced Epithelial to Mesenchymal Transition in NSCLC Cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Sequential platinum-based chemotherapy-thoracic radiotherapy in early stage non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Clinical issues in the management of non-small-cell lung cancer and the role of platinum-based therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Cx43 reverses the resistance of A549 lung adenocarcinoma cells to cisplatin by inhibiting EMT.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Inhibition of ZEB1 reverses EMT and chemoresistance in docetaxel-resistant human lung adenocarcinoma cell line

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Integrin beta 1 enhances the epithelial-mesenchymal transition in association with gefitinib resistance of non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

The therapeutic potential of targeting the epithelial-mesenchymal transition in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Metformin inhibits the IL-6-induced epithelial-mesenchymal transition and lung adenocarcinoma growth and metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

EMT twists the road to PI3K.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Epithelial-to-mesenchymal transition rewires the molecular path to PI3K-dependent proliferation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic roles and therapeutic potential

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Suppression of metastases of small cell lung cancer cells in mice by a peptidic CXCR4 inhibitor TF14016.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Development of novel CXCR4-based therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Acquisition of epithelial-mesenchymal transition phenotype and cancer stem cell-like properties in cisplatin-resistant lung cancer cells through AKT/β-catenin/Snail signaling pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Targeting the transforming growth factor-beta signaling pathway in human cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

An novel inhibitor of TGF-β type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial-mesenchymal transition

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Wnt signaling pathway in non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Wnt signaling pathway pharmacogenetics in non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the CellSearch Assay™ and the isolation by size of epithelial tumor cell method.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-24932-2_3

10.1007/978-3-319-24932-2_3

31 March 2020

Identifiers

DOI

1 reference

5 September 2017

1 reference

PubMed ID

26703798